Safety, tolerability, pharmacokinetics and pharmacodynamics of losmapimod following a single intravenous or oral dose in healthy volunteers.
about
Emerging treatment options to improve cardiovascular outcomes in patients with acute coronary syndrome: focus on losmapimodp38 MAPK in cardioprotection - are we there yet?Therapeutic potential of p38 MAP kinase inhibition in the management of cardiovascular disease.Safety, tolerability, pharmacokinetics, and pharmacodynamics of losmapimod in healthy Japanese volunteers.Evaluation of antidepressant properties of the p38 MAP kinase inhibitor losmapimod (GW856553) in Major Depressive Disorder: Results from two randomised, placebo-controlled, double-blind, multicentre studies using a Bayesian approach.The TAB1-p38α complex aggravates myocardial injury and can be targeted by small molecules
P2860
Safety, tolerability, pharmacokinetics and pharmacodynamics of losmapimod following a single intravenous or oral dose in healthy volunteers.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Safety, tolerability, pharmaco ...... al dose in healthy volunteers.
@en
type
label
Safety, tolerability, pharmaco ...... al dose in healthy volunteers.
@en
prefLabel
Safety, tolerability, pharmaco ...... al dose in healthy volunteers.
@en
P2093
P2860
P356
P1476
Safety, tolerability, pharmaco ...... ral dose in healthy volunteers
@en
P2093
Adam T McGeoch
April M Barbour
Dennis L Sprecher
Gengqian Cai
Johann Graggaber
Lea Sarov-Blat
Michael J Fossler
P2860
P304
P356
10.1111/BCP.12063
P407
P577
2013-07-01T00:00:00Z